Behind the science

Emerging evidence suggests that climate change could be worsening #AntiMicrobialResistance. Another sign of how climate and health are closely connected. We're working hard to reduce our climate impact and to find new tools to help get ahead of #AMR, together. twitter.com/wellcometrust/…

Organ damage impacts many people living with #lupus within 5 years of diagnosis. A new global survey of healthcare professionals suggests conversations with patients about #SLE organ damage risk may not be happening early enough in course of disease. gsk.to/3EMv4wz

Excellent news from @DHSCgovuk today with investment to support UK status as a #ScienceSuperpower. The UK life sciences sector delivers transformational medicines and vaccines to patients around the world, while also being a key generator of jobs and growth. twitter.com/DHSCgovuk/stat…

An estimated 37m people in the Greater Horn of Africa region are facing acute food insecurity due to conflict and extreme weather. We're contributing £1m to @savechildrenuk and @Amref_UK to treat children with malnutrition and provide access to health services.

#WorldAntimicrobialAwarenessWeek is once a year, but we’re working hard every day to get ahead of #AMR together – from supporting surveillance and stewardship to R&D into potential therapies and vaccines. Go #BehindtheScience to learn more 👇gsk.com/en-gb/behind-t…Z

#AntimicrobialResistance means that antibiotics are becoming less effective. That can impact even common conditions like urinary tract infections. So we’re working hard to find new tools to help us get ahead of #AMR, together. #WAAW gsk.com/en-gb/behind-t…

It’s #WAAW, take #AMomentToReset and find out how we can get ahead of AMR, together. Antibiotics are a cornerstone of modern healthcare but #AntimicrobialResistance means they’re becoming less effective. Left unchecked, #AMR could claim 10M lives by 2050.

This #WorldCOPDDay we are discussing the importance of treatable traits in #COPD and how they can guide tailored treatment decisions to improve symptoms, reduce the burden of exacerbations and improve the lives of those impacted by the disease.

The 2023 GOLD recommendations continue to simplify the approach to COPD diagnosis and management, with a focus on improving patient’s symptoms and reducing risk of exacerbations. This is consistent with GSK’s scientific position and reflect what is best for patients. twitter.com/GOLD_COPD/stat…

Sharai, Automation Engineering Associate, is on rotation in the GSK graduate scheme where she receives the first-class support she needs to thrive as she grows her career. Hear her story 👇 #AheadTogetherrZ